286 related articles for article (PubMed ID: 22923450)
1. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.
Yin S; Kaluz S; Devi NS; Jabbar AA; de Noronha RG; Mun J; Zhang Z; Boreddy PR; Wang W; Wang Z; Abbruscato T; Chen Z; Olson JJ; Zhang R; Goodman MM; Nicolaou KC; Van Meir EG
Clin Cancer Res; 2012 Dec; 18(24):6623-33. PubMed ID: 22923450
[TBL] [Abstract][Full Text] [Related]
2. Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma.
Dong L; You S; Zhang Q; Osuka S; Devi NS; Kaluz S; Ferguson JH; Yang H; Chen G; Wang B; Grossniklaus HE; Van Meir EG
Clin Cancer Res; 2019 Apr; 25(7):2206-2218. PubMed ID: 30563937
[TBL] [Abstract][Full Text] [Related]
3. Menadione and ethacrynic acid inhibit the hypoxia-inducible factor (HIF) pathway by disrupting HIF-1α interaction with p300.
Na YR; Han KC; Park H; Yang EG
Biochem Biophys Res Commun; 2013 May; 434(4):879-84. PubMed ID: 23618863
[TBL] [Abstract][Full Text] [Related]
4. Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.
Reece KM; Richardson ED; Cook KM; Campbell TJ; Pisle ST; Holly AJ; Venzon DJ; Liewehr DJ; Chau CH; Price DK; Figg WD
Mol Cancer; 2014 Apr; 13():91. PubMed ID: 24775564
[TBL] [Abstract][Full Text] [Related]
5. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.
Wang W; Ao L; Rayburn ER; Xu H; Zhang X; Zhang X; Nag SA; Wu X; Wang MH; Wang H; Van Meir EG; Zhang R
PLoS One; 2012; 7(9):e44883. PubMed ID: 23028659
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents.
Wei J; Yang Y; Lu M; Lei Y; Xu L; Jiang Z; Xu X; Guo X; Zhang X; Sun H; You Q
Mini Rev Med Chem; 2018; 18(4):296-309. PubMed ID: 27484627
[TBL] [Abstract][Full Text] [Related]
7. RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model.
Gillespie DL; Aguirre MT; Ravichandran S; Leishman LL; Berrondo C; Gamboa JT; Wang L; King R; Wang X; Tan M; Malamas A; Lu ZR; Jensen RL
J Neurosurg; 2015 Feb; 122(2):331-41. PubMed ID: 25423275
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.
Mooring SR; Jin H; Devi NS; Jabbar AA; Kaluz S; Liu Y; Van Meir EG; Wang B
J Med Chem; 2011 Dec; 54(24):8471-89. PubMed ID: 22032632
[TBL] [Abstract][Full Text] [Related]
9. Vitexin enhances radiosensitivity of mouse subcutaneous xenograft glioma by affecting the miR-17-5p/miR-130b-3p/PTEN/HIF-1α pathway.
Xie T; Ding YH; Sang CS; Lin ZX; Dong J; Fu XA
Strahlenther Onkol; 2024 Jun; 200(6):535-543. PubMed ID: 38453699
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent.
Mun J; Jabbar AA; Devi NS; Liu Y; Van Meir EG; Goodman MM
Bioorg Med Chem; 2012 Jul; 20(14):4590-7. PubMed ID: 22682301
[TBL] [Abstract][Full Text] [Related]
11. Visualization of hypoxia-inducible factor 1α-p300 interactions in live cells by fluorescence resonance energy transfer.
Kim SY; Lee MJ; Na YR; Kim SY; Yang EG
J Cell Biochem; 2014 Feb; 115(2):271-80. PubMed ID: 23966271
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.
Duyndam MC; van Berkel MP; Dorsman JC; Rockx DA; Pinedo HM; Boven E
Biochem Pharmacol; 2007 Jul; 74(2):191-201. PubMed ID: 17498666
[TBL] [Abstract][Full Text] [Related]
13. Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor.
Shi Q; Yin S; Kaluz S; Ni N; Devi NS; Mun J; Wang D; Damera K; Chen W; Burroughs S; Mooring SR; Goodman MM; Van Meir EG; Wang B; Snyder JP
ACS Med Chem Lett; 2012 Aug; 3(8):620-5. PubMed ID: 24936238
[TBL] [Abstract][Full Text] [Related]
14. Suppressing the malignant phenotypes of glioma cells by lentiviral delivery of small hairpin RNA targeting hypoxia-inducible factor-1α.
Dong CG; Wu WK; Feng SY; Yu J; Shao JF; He GM
Int J Clin Exp Pathol; 2013; 6(11):2323-32. PubMed ID: 24228093
[TBL] [Abstract][Full Text] [Related]
15. Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.
Mun J; Jabbar AA; Devi NS; Yin S; Wang Y; Tan C; Culver D; Snyder JP; Van Meir EG; Goodman MM
J Med Chem; 2012 Aug; 55(15):6738-50. PubMed ID: 22746274
[TBL] [Abstract][Full Text] [Related]
16. Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.
Lo Dico A; Martelli C; Valtorta S; Raccagni I; Diceglie C; Belloli S; Gianelli U; Vaira V; Politi LS; Bosari S; Lucignani G; Moresco RM; Ottobrini L
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1093-105. PubMed ID: 25813354
[TBL] [Abstract][Full Text] [Related]
17. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
[TBL] [Abstract][Full Text] [Related]
18. Anticancer osmium complex inhibitors of the HIF-1α and p300 protein-protein interaction.
Yang C; Wang W; Li GD; Zhong HJ; Dong ZZ; Wong CY; Kwong DW; Ma DL; Leung CH
Sci Rep; 2017 Feb; 7():42860. PubMed ID: 28225008
[TBL] [Abstract][Full Text] [Related]
19. Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity.
Wang KS; Ma J; Mi C; Li J; Lee JJ; Jin X
Oncol Rep; 2016 Apr; 35(4):2045-52. PubMed ID: 26781327
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
